Lipid lowering in patients with chronic kidney disease: A SHARP turn in the wrong direction?

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 18, Issue 6, 2011, Pages 858-861

  Berthold, Heiner K ^a   Krone, Wilhelm ^b   Erdmann, Erland ^b   Gouni Berthold, Ioanna ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chronic kidney disease; Ezetimibe; Lipid lowering; Statins

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DRUG EFFECT; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; VASCULAR DISEASE;

EID: 84856863271     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/1741826711423116     Document Type: Review

References (18)

1. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360(14): 1395-1407.
2. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238-248. (Pubitemid 41058323)
3. Tonelli M, Moye L, Sacks FM, Kiberd B and Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138(2): 98-104. (Pubitemid 36222496)
4. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A and Reed DP. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009; 53(5): 741-750.
5. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110(12): 1557-1563. (Pubitemid 39297976)
6. Collins R, Armitage J, Parish S, Sleigh P and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005-2016.
7. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD007784.
8. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51(15): 1448-1454. (Pubitemid 351471787)
9. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-2192.
10. Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, et al. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. Eur J Cardiovasc Prev Rehabil 2009; 16(3): 315-320.
11. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24(8): 1329-1330. (Pubitemid 39050420)
12. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55(24): 2721-2726.
13. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358(14): 1431-1443. (Pubitemid 351482735)
14. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W and Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipo-proteins in healthy men: a randomized trial. Eur Heart J 2010; 31(13): 1633-1639.
15. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376(9753): 1658-1669.
16. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359(8): 789-799.
17. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336(7645): 645-651. (Pubitemid 351481234)
18. Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC and Strippoli GF. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2009; CD004289.